Cargando…

IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan

BACKGROUND: The insulin receptor substrate 1 (IRS1) is a critical factor in the signaling pathway for insulin, and mutations in this gene have been reported, which contribute to the ability to develop type 2 diabetes. The polymorphisms in the promoter region of C‐C motif chemokine receptor5 (CCR5) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Keshavarzi, Fatemeh, Golsheh, Shadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503169/
https://www.ncbi.nlm.nih.gov/pubmed/30884193
http://dx.doi.org/10.1002/mgg3.631
_version_ 1783416370342395904
author Keshavarzi, Fatemeh
Golsheh, Shadi
author_facet Keshavarzi, Fatemeh
Golsheh, Shadi
author_sort Keshavarzi, Fatemeh
collection PubMed
description BACKGROUND: The insulin receptor substrate 1 (IRS1) is a critical factor in the signaling pathway for insulin, and mutations in this gene have been reported, which contribute to the ability to develop type 2 diabetes. The polymorphisms in the promoter region of C‐C motif chemokine receptor5 (CCR5) are also being studied as candidates for susceptibility to develop type 2 diabetes. The aim of the current study was to determine the relationship between IRS1 and CCR5 polymorphisms with type 2 diabetes in the Kurdistan population. METHODS: Genomic DNA was isolated from the blood by salt extraction method and the polymorphisms were examined using Restriction Fragment Length Polymorphism (RFLP) method. RESULTS: The results of current study indicated that the frequency of AA genotype in type 2 diabetic patients in both CCR5 (OR = 2.9, p = 0.04) and IRS1 (OR = 3.3, p = 0.036) were significantly more than controls. CONCLUSION: According to the results of this study, the presence of AA genotype in both CCR5 and IRS1 is associated with type 2 diabetes. There was no significant association between AG or GG genotypes with type 2 diabetes.
format Online
Article
Text
id pubmed-6503169
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65031692019-05-10 IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan Keshavarzi, Fatemeh Golsheh, Shadi Mol Genet Genomic Med Original Articles BACKGROUND: The insulin receptor substrate 1 (IRS1) is a critical factor in the signaling pathway for insulin, and mutations in this gene have been reported, which contribute to the ability to develop type 2 diabetes. The polymorphisms in the promoter region of C‐C motif chemokine receptor5 (CCR5) are also being studied as candidates for susceptibility to develop type 2 diabetes. The aim of the current study was to determine the relationship between IRS1 and CCR5 polymorphisms with type 2 diabetes in the Kurdistan population. METHODS: Genomic DNA was isolated from the blood by salt extraction method and the polymorphisms were examined using Restriction Fragment Length Polymorphism (RFLP) method. RESULTS: The results of current study indicated that the frequency of AA genotype in type 2 diabetic patients in both CCR5 (OR = 2.9, p = 0.04) and IRS1 (OR = 3.3, p = 0.036) were significantly more than controls. CONCLUSION: According to the results of this study, the presence of AA genotype in both CCR5 and IRS1 is associated with type 2 diabetes. There was no significant association between AG or GG genotypes with type 2 diabetes. John Wiley and Sons Inc. 2019-03-18 /pmc/articles/PMC6503169/ /pubmed/30884193 http://dx.doi.org/10.1002/mgg3.631 Text en © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Keshavarzi, Fatemeh
Golsheh, Shadi
IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan
title IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan
title_full IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan
title_fullStr IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan
title_full_unstemmed IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan
title_short IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan
title_sort irs1‐ rs10498210 g/a and ccr5‐59029 a/g polymorphisms in patients with type 2 diabetes in kurdistan
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503169/
https://www.ncbi.nlm.nih.gov/pubmed/30884193
http://dx.doi.org/10.1002/mgg3.631
work_keys_str_mv AT keshavarzifatemeh irs1rs10498210gaandccr559029agpolymorphismsinpatientswithtype2diabetesinkurdistan
AT golshehshadi irs1rs10498210gaandccr559029agpolymorphismsinpatientswithtype2diabetesinkurdistan